Hippocratic AI emerged from stealth, as well as announced $50 million in seed funding through a round co-led by General Catalyst and Andreessen Horowitz. The Palo Alto-based startup bills itself as the first large language model designed specifically for healthcare.
Bayesian Health, a startup created by a machine learning researcher at Johns Hopkins, is building models for sepsis detection, patient deterioration and bedsores. The company recently emerged from stealth mode with backing from Andreessen Horowitz.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Dyno Therapeutics’ technology for designing viral vectors that deliver gene therapies has led to partnerships with Novartis, Sarepta Therapeutics, and Roche. With the Series A financing, the startup plans to expand its technology to address more tissue types, and potentially add more partners.
Headway, a startup working to build a network of therapists covered by major insurers, raised $70 million in funding. The startup manages claims, credentialing and other administrative work for independent practices.
Komodo Health raised a $50 million funding round led by Andreessen Horowitz. The software company is building up a trove of healthcare data to drive better analytics.
Here's how the San Francisco company went from being an investor darling valued at $600 million to being under investigation by the FBI for its corporate practices.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Medicare Advantage startup pitches itself as a "payvidor" as it goes against a host of competitors including Bright Health, Clover Health and Oscar Health.
How can the new big medical investor make a big difference?
Software venture firm Andreessen Horowitz has created a $200 million 'bio fund' to finance startups that operate at the intersection of software and biotechnology.